Start here if you're new
what it is
Argenx sells immune-disease medicines, led by VYVGART, a treatment that removes harmful antibodies driving autoimmune attacks.
how it gets paid
Last year Argenx Se made $4M in revenue.
what just happened
Argenx's latest update said 2025 revenue reached $4.2B, beating the $3.9B consensus cited in post-results coverage.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
35.3x trailing p/e — you're paying up for this one
47.0% return on capital — every dollar works hard here
xvary composite: 58/100 — below average
$38.00 fy2027 eps est
What they do
argenx sells immune-disease medicines, led by VYVGART, a treatment that removes harmful antibodies driving autoimmune attacks.
VYVGART was first to market in FcRn blocking (FcRn blocking → clearing harmful antibodies faster → fewer autoimmune attacks). If your doctor already knows the drug and now has a pre-filled syringe option, switching gets harder. That helps explain why revenue jumped 90% in 2025 while operating margin hit 50.0%.
How they make money
$4M
annual revenue
total revenue
$4M
n/a
The products that matter
marketed autoimmune therapy
VYVGART
$4.15B net sales · +90% last year
it's the entire current revenue engine. A 90% jump to $4.15B tells you demand is real. It also tells you concentration risk is real because there is no second commercial product carrying the load.
the entire current story
registrational pipeline
ARGX-213 / ARGX-121
H1 2026 readouts · five registrational readouts in 2026
this is where you find out whether ARGX is building a broader immunology platform or just extending one winner. The snapshot says five registrational readouts land in 2026, and success here could add $5–10B in market value.
where the rerating lives
market expansion inside mg
MG expansion
17,000 to 60,000 patients by 2030
management says the addressable myasthenia gravis market can rise from 17,000 patients today to 60,000 by 2030 through seronegative, ocular, and biologics segments. That gap explains why the stock trades like the franchise still has a lot of runway.
label expansion bet
Key numbers
50.0%
operating margin
Operating margin → the share of sales left after running the business → half of revenue is turning into operating profit, which is rare in biotech.
47.0%
return on capital
Return on capital → profit earned on the money invested in the business → argenx is turning investment into earnings far better than most drug developers.
35.3x
trailing multiple
Trailing multiple → how expensive the stock looks versus the last 12 months of profit → you are paying a premium for continued execution.
$12B
2029 revenue
That estimate is the whole bull case in one line: the market expects today's franchise to become a much larger machine.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 40 / 100
- net profit margin 41.0% — keeps 41 cents of every dollar in revenue
- return on equity 47% — $0.47 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in ARGX 3 years ago → it's now worth $21,950.
The index would have given you $13,880.
source: institutional data · total return
What just happened
beat estimates
argenx's latest update said 2025 revenue reached $4.2B, beating the $3.9B consensus cited in post-results coverage.
The year ended with quarterly earnings per share of $5.70, versus $1.39 in 2024's third quarter and $11.79 in 2024's fourth quarter history from the prior year base. The driver was simple: VYVGART kept scaling, and the company finished 2025 with a 50.0% operating margin.
$4.2B
2025 revenue
$5.70
q4 earnings per share
50.0%
operating margin
the number that mattered
$4.2B mattered most because this is still a one-franchise story, and that sales base funds everything else you are paying for.
-
argenx se posted spectacular preliminary results for 2025.fully-audited results are expected to be released by the end of february, but the company announced net sales of $4.15 billion.
-
this represented a 90% surge over the previous year's top line.the company's sole drug, vyvgart, is highly sought by those suffering from a rare neuromuscular disease, myasthenia gravis. we tentatively estimate that earnings momentum will continue through 2027. we look for earnings to come in at roughly $28.00 per share this year, and approximate $38.00 per share in 2027.
-
vyvgart looks well-entrenched as the best solution for myasthenia gravis (mg).although competition exists, primarily from astrazeneca, argenx's solution appears superior for now from both efficacy and safety perspectives. u.s. manufacturing capabilities are being expanded, since pipeline growth is reportedly positive (see below).
-
the market position was enhanced recently by a new pre-filled syringe product.management contends that the market will rise to 60,000 addressable patients by 2030, from 17,000, thanks to seronegative (an fda decision is expected by year-end), ocular, and biologics markets within the overall mg market. Five registrational readouts are scheduled for this year.
-
investors may gain a greater sense of the potential to penetrate new markets.registrational readouts for multifocal motor neuropathy, thyroid eye disease, idiopathic inflammatory myopathy, and immune thrombocytopenia will likely be conducted. this neutrally ranked stock is suitable for aggressive growth investors that are able to tolerate risk. granted, this high-flying biotechnology equity has a perfect growth consistency score and an average risk rank. however, future prospects are not well defined, and neutrally-ranked argenx stock carries a lofty p/e multiple.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
all $4.15B in reported 2025 net sales came from one product.
high
One-drug concentration
The business still revolves around VYVGART. Quiet part out loud: when one medicine carries the story, any slowdown in new uses or competition hits the whole stock fast.
threatens about $3.65B of revenue tied to the U.S. market alone, based on 87% of roughly $4.2B 2025 sales
med
Expectations already huge
The stock trades at 35.3 times trailing earnings (price-to-earnings ratio → how much investors pay for each dollar of profit → you are already paying up). Great execution is required just to stand still.
could shave about $116 per share, or 14.1%, down to the 18-month low range of $706
med
Pipeline mood swings
You are not just buying today’s sales. You are buying future disease approvals, and biotech stocks punish delays hard when the next trial reads poorly.
the stock has already shown 10% downside moves around pipeline concerns, based on reported post-results trading
If VYVGART keeps expanding, you are fine. If growth slips, this stock has very little patience.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
may 6, 2026 earnings
This is the first real check after the stock dropped 10% on preliminary Q1 sales of $790M. You want to know whether that was a one-quarter wobble or the first sign that comps are getting harder.
franchise depth
VYVGART demand inside MG and CIDP
The core franchise still has to do heavy lifting while the pipeline matures. If uptake keeps broadening, the one-drug story looks more durable. If it flattens, concentration risk gets louder.
pipeline
H1 2026 ARGX-213 and ARGX-121 readouts
The source says success here could add $5–10B to market cap. In human-speak: these are not side quests. They are part of the case for why this should be valued as more than one commercial asset.
valuation
the gap between $4.15B today and the $12B sales path implied for 2029
You do not need perfect precision here. You need direction. If new indications and readouts are not closing that gap, the current valuation starts looking ahead of itself.
Analyst rankings
2026 earnings view
$28.00 growth
the source looks for roughly $28.00 in EPS this year. the street still expects acceleration, not digestion.
2027 earnings view
$38.00 higher
another big step up. if that path slips, the premium setup gets harder to defend.
risk rank
3 mid
in human-speak: not a bunker stock, not the wildest biotech on the board either.
xvary composite
58 / 100 below avg
good business, demanding setup. that's what happens when the fundamentals are strong and the expectations are stronger.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 262 buyers vs. 188 sellers in 3q2025. total institutional holdings: 30.5M shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$706
$1398
$822
current price
$2158
target midpoint · +162% from current · 3-5yr high: $2590 (+215% · 33% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive